Cancer Discov. 2018 Dec;8(12):1499-1500. doi: 10.1158/2159-8290.CD-NB2018-139. Epub 2018 Oct 26.
A case report highlights a novel, rare mechanism of resistance to chimeric antigen receptor (CAR) T-cell therapy, conferred by the accidental transduction of a single leukemic B cell with the anti-CD19 CAR (CAR19) gene during therapy manufacturing. Because CAR19 bound directly to CD19 on the cell surface-a phenomenon called in cis epitope masking-the therapeutic target was effectively hidden from reprogrammed T cells.
一份病例报告突出了一种对嵌合抗原受体（CAR）T细胞疗法产生耐药性的新型罕见机制，该机制是在治疗制备过程中，单个白血病B细胞意外转导了抗CD19 CAR（CAR19）基因所致。由于CAR19直接与细胞表面的CD19结合——这种现象称为顺式表位掩盖——治疗靶点有效地从重新编程的T细胞中隐藏起来。
